查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714780

全球幹細胞治療市場按治療類型、細胞來源、最終用戶、應用、治療領域分類——預測至 2025 年至 2030 年

Stem Cell Therapy Market by Therapy Type, Cell Source, End User, Application, Therapeutic Areas - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2023 年幹細胞治療市值將達到 39.1 億美元，到 2024 年將以 14.27% 的複合年成長率成長至 44.5 億美元，到 2030 年將達到 99.5 億美元。

主要市場統計數據
基準年2023年 39.1億美元
預計2024年 44.5億美元
預測年份 2030 99.5億美元
複合年成長率（%） 14.27%

幹細胞治療是現代醫學中最有前景的前沿領域之一，為再生醫學和疾病管理開闢了新的途徑。這個創新領域利用幹細胞的獨特特性來修復受損組織、恢復功能並為傳統治療失敗的患者帶來希望。近年來，對幹細胞基礎生物學的廣泛研究為從退化性疾病到急性損傷等各種疾病的突破性治療方法鋪平了道路。

細胞分離技術、培養方法和基因組分析的不斷改進不僅提高了這些治療方法的安全性和有效性，而且拓寬了它們的潛在應用。隨著科學界和監管機構更加緊密地合作建立框架和通訊協定，將幹細胞技術納入主流醫療保健變得越來越可行。本介紹為更廣泛的討論奠定了基礎，即新興趨勢和技術進步如何重塑醫療保健格局並開創個人化和再生醫學的新時代。

透過進行夥伴關係以及保持強力的臨床檢驗，幹細胞治療市場有望改變曾經被認為遙不可及的臨床實踐和患者結果。

改變幹細胞治療市場

近年來，在科學快速進步和市場動態的推動下，幹細胞治療領域發生了重大變化。尖端生物技術的整合促進了從實驗療法到臨床核准治療方法的轉變，並重新定義了不同醫學學科的治療策略。總的來說，細胞重編程、改善培養條件和精準醫療的創新方法正在促成模式轉移，個人化醫療正成為實際的現實。

這項進步以對幹細胞行為更深入的科學理解為基礎，使研究人員能夠克服先前在細胞活力和分化方面的限制。研究和臨床試驗強調了利用多種細胞來源的重要性，包括異體幹細胞、誘導性多功能幹細胞和周產期幹細胞。

嚴格的監管途徑和技術進步的出現繼續為相關人員提供信心。經濟考量、資金籌措機會和策略合作正在進一步加快該領域的創新步伐。市場促進因素的整合將使產業更具彈性、資料主導，並能夠透過再生醫學來應對複雜的醫療保健挑戰。

幹細胞治療的全面市場細分洞察

了解市場區隔的細微差別對於駕馭複雜的幹細胞治療生態系統至關重要。市場分析受到多種細分因素的驅動，這些因素量化了治療方法和研究應用的多樣性。主要細分之一是基於治療類型，從而可以透過同種異體和自體移植方法對市場進行評估。無論幹細胞來自捐贈者或患者自身，每種治療方法都有其獨特的優勢，可以影響安全性、有效性和個人化治療方法。

第二個重要方面是基於細胞來源的研究。本研究將探討成體幹細胞、胚胎幹細胞、誘導性多功能幹細胞和周產期幹細胞，並著重於每種細胞的治療潛力和限制。成體幹細胞的分析研究正受到越來越多的關注，特別是透過對造血幹細胞、間質幹細胞和神經幹細胞的研究。類似地，將透過評估周產期幹細胞來自羊水、胎盤和臍帶的來源來進行仔細檢查。這種詳細的分類提供了對每種細胞類型的相對優點和潛在臨床應用的深入了解。

市場根據最終用戶細分，例如學術和研究機構、生物技術和製藥公司以及醫院和專科診所。這種細分反映了對研究創新、治療發展和以患者為中心的護理模式的不同需求。此外，按應用細分突顯了幹細胞療法在藥物發現和開發、再生醫學、組織工程等領域的應用。另一個細分領域則專注於治療領域，心血管疾病、血液學、肌肉骨骼疾病、神經系統疾病和腫瘤學是再生療法的主要目標。這種多方面的分析不僅強調了幹細胞研究的應用廣度，也強調了解決特定醫學挑戰所需的個人化方法。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球老化和對幹細胞治療潛力的認知不斷提高
      • 政府措施和有利的法規結構正在刺激幹細胞研究的進步
      • 慢性病的增多推動了對先進幹細胞療法的需求。
    • 限制因素
      • 幹細胞治療的高成本限制了患者和醫療保健提供者獲得治療的機會
    • 機會
      • 增加公共和私人對研發活動的投資
      • 基於細胞的技術的進步正在提高幹細胞治療的功效和適用性。
    • 任務
      • 了解幹細胞治療相關的各種監管環境
      • 圍繞幹細胞使用的倫理問題和公眾認知
  • 市場區隔分析
    • 治療類型：自體免疫疾病的治療越來越廣泛，以最大限度地降低免疫排斥和感染疾病傳播的風險。
    • 細胞來源：神經幹細胞增殖的重要性在於它們能夠分化成中樞神經系統內的各種細胞類型
    • 最終用戶：生物技術和製藥公司擴大採用幹細胞療法來治療神經退化性疾病疾病和心血管疾病
    • 應用：疾病建模能力將增加藥物發現和開發中的應用
    • 治療領域：幹細胞療法透過心臟修復和再生對心血管疾病的顯著益處
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 幹細胞治療市場（依治療類型）

  • 順勢療法
  • 自體移植治療

第7章 幹細胞治療市場 Cell Source

  • 成體幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
  • 胚胎幹細胞
  • 誘導多功能細胞
  • 周產期幹細胞
    • 羊水幹細胞
    • 胎盤幹細胞
    • 臍帶幹細胞

第 8 章 幹細胞治療市場（依最終使用者）

  • 學術研究所
  • 生物技術和製藥公司
  • 醫院和專科診所

第9章 幹細胞治療市場：依應用

  • 藥物研發
  • 再生醫學
  • 組織工程

第 10 章 幹細胞治療市場（依治療領域）

  • 心血管疾病
  • 血液學
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 腫瘤學

第 11 章：美洲幹細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區幹細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲幹細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Anterogen Co., Ltd.
  • Astellas Pharma Inc.
  • Beike Biotechnology Co., Ltd.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • CellProthera SAS
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Garuda Therapeutics
  • Holostem Terapie Avanzate Srl
  • Jasper Therapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Juvena Therapeutics Inc.
  • Kangstem Biotech Co., Ltd.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Lonza Group AG
  • Medeze Group
  • Merck KGaA
  • Mesoblast Ltd.
  • Novo Nordisk A/S
  • Plasticell
  • ReNeuron Group PLC
  • SQZ Biotechnologies Company by Stemcell Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • US Stem Cell Inc
  • Umoja Biopharma
  • Vericel Corporation
Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 3.91 billion in 2023 and is projected to grow to USD 4.45 billion in 2024, with a CAGR of 14.27%, reaching USD 9.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 3.91 billion
Estimated Year [2024] USD 4.45 billion
Forecast Year [2030] USD 9.95 billion
CAGR (%) 14.27%

Stem cell therapy represents one of the most promising frontiers in modern medicine, opening new avenues for regenerative treatments and disease management. This innovative field harnesses the distinctive properties of stem cells to repair damaged tissues, restore functionality, and offer patients hope where conventional treatments may fall short. In recent years, extensive research has driven a better understanding of the underlying biology of stem cells, paving the way for breakthrough therapies that target a range of conditions from degenerative disorders to acute injuries.

The continuous refinement in cell isolation techniques, culture methods, and genomic profiling has not only increased the safety and efficacy of these therapies but also expanded their potential applications. As the scientific community and regulatory bodies work more closely to establish frameworks and protocols, the integration of stem cell technology into mainstream healthcare is becoming increasingly feasible. This introduction sets the stage for a broader discussion on how emerging trends and technological advances are reshaping the landscape, ushering in a new era of personalized and regenerative medicine.

By embracing interdisciplinary research, fostering public and private partnerships, and maintaining robust clinical validations, the stem cell therapy market is poised to transform both clinical practices and patient outcomes in a manner that was once considered out of reach.

Transformative Shifts in the Stem Cell Therapy Landscape

Recent years have been marked by transformative shifts in the landscape of stem cell therapy, driven by rapid scientific advancements and evolving market dynamics. The integration of state-of-the-art biotechnologies has facilitated the progression from experimental phases to clinically approved treatments, thereby redefining therapeutic strategies across diverse medical disciplines. Innovative methods in cell reprogramming, enhanced culture conditions, and precision medicine have collectively contributed to a paradigm shift where personalized care is becoming a tangible reality.

This evolution is underpinned by a deeper scientific understanding of stem cell behavior that has enabled researchers to overcome previous limitations related to cell viability and differentiation. Research and clinical trials have not only highlighted the therapeutic potential of both allogeneic and autologous approaches but have also underscored the importance of harnessing varied cell sources such as adult, embryonic, induced pluripotent, and perinatal stem cells.

The emergence of rigorous regulatory paths, combined with technological advancements, continues to instill confidence in stakeholders. Economic considerations, funding opportunities, and strategic collaborations are further accelerating the pace of innovation in this sector. As market drivers converge, the result is an industry that is more resilient, data-driven, and capable of addressing complex healthcare challenges through regenerative medicine.

Comprehensive Market Segmentation Insights in Stem Cell Therapy

Understanding the nuances of market segmentation is critical to navigating the complex ecosystem of stem cell therapy. The market analysis is driven by multiple segmentation factors that quantify the diversity in treatment modalities and research applications. One primary segmentation is based on therapy type, where the market is evaluable both under allogeneic and autologous approaches. Each method brings distinct advantages, whether deriving stem cells from donors or patients themselves, thereby influencing safety, efficacy, and personalized treatment options.

A second pivotal dimension is the investigation based on cell source. The research examines adult stem cells, embryonic stem cells, induced pluripotent stem cells, and perinatal stem cells to discern their therapeutic potential and limitations. Adult stem cells receive further analytical attention, particularly through the study of hematopoietic, mesenchymal, and neural stem cells, each contributing unique properties that influence treatment outcomes. Similarly, perinatal stem cells are scrutinized by evaluating amniotic fluid, placental, and umbilical cord sources. This granular breakdown provides insights into the relative merits and clinical applicability of each cell type.

The market is further divided according to end user segments-academic and research institutions, biotechnology and pharmaceutical companies, and hospitals and specialty clinics. Such segmentation reflects the varying demands for research innovation, therapy development, and patient-centered treatment models. Additionally, the application-based segmentation emphasizes the utilization of stem cell therapies in drug discovery and development, regenerative medicine, and tissue engineering. Another segmentation area focuses on therapeutic areas, where cardiovascular diseases, hematology, musculoskeletal disorders, neurological disorders, and oncology are the primary targets of regenerative interventions. This multidimensional analysis not only highlights the expansive application of stem cell research but also underscores the tailored approaches that are required to address specific medical challenges.

Based on Therapy Type, market is studied across Allogeneic Therapy and Autologous Therapy.

Based on Cell Source, market is studied across Adult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Perinatal Stem Cells. The Adult Stem Cells is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Neural Stem Cells. The Perinatal Stem Cells is further studied across Amniotic Fluid Stem Cells, Placental Stem Cells, and Umbilical Cord Stem Cells.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology & Pharmaceutical Companies, and Hospitals & Specialty Clinics.

Based on Application, market is studied across Drug Discovery and Development, Regenerative Medicine, and Tissue Engineering.

Based on Therapeutic Areas, market is studied across Cardiovascular Diseases, Hematology, Musculoskeletal Disorders, Neurological Disorders, and Oncology.

Global Regional Dynamics in the Stem Cell Therapy Market

Regional dynamics play a crucial role in mapping the global landscape of stem cell therapy. Market trends and regulatory approvals exhibit distinct patterns across different regions. In the Americas, robust investment in biomedical research and well-established healthcare infrastructures are significant drivers for the adoption of advanced stem cell therapies. The region's diverse population and proactive public-private partnerships have spurred rapid development and clinical trials that continue to influence global standards.

Meanwhile, in regions encompassing Europe, the Middle East, and Africa, a blend of tradition and innovation is pushing forward progressive healthcare agendas. Researchers and policymakers in these areas are increasingly focused on developing localized therapies that address region-specific health challenges while aligning with international protocols. The strengthening of regulatory frameworks in these regions further supports the safe and effective integration of stem cell therapies into routine clinical practice.

In the Asia-Pacific region, rapid economic growth combined with a significant increase in research funding has positioned the area as a burgeoning hub for biotechnology and regenerative medicine. Driven by expansive clinical research, technological adoption, and a rising middle-class demand for advanced healthcare solutions, the Asia-Pacific markets are progressively adopting novel stem cell therapies. This tripartite regional overview provides a comprehensive understanding of how local trends, regulatory environments, and economic factors interplay to shape the global market landscape of stem cell therapy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Stem Cell Therapy Advancements

Numerous pioneering companies are at the vanguard of driving advancements in the stem cell therapy space. Industry leaders such as Anterogen Co., Ltd. and Astellas Pharma Inc. are continuously adopting innovative approaches to developing breakthrough therapies. These companies, along with emerging innovators like Beike Biotechnology Co., Ltd. and BrainStorm Cell Therapeutics Inc., are instrumental in translating cutting-edge research into clinically effective solutions. Notable pharmaceutical giants like Bristol-Myers Squibb Company and Kite Pharma, Inc. under Gilead Sciences, Inc. have also contributed significantly by leveraging their extensive research networks and global resources to propel stem cell therapies forward.

Other prominent market players, including CellProthera SAS, Fate Therapeutics, Inc., and Gamida Cell Ltd., are recognized for their focus on enhancing the differentiation processes and ensuring consistent quality across therapeutic applications. Companies such as Garuda Therapeutics and Holostem Terapie Avanzate S.r.l. have further diversified the landscape by exploring novel cell sources and addressing unmet clinical needs. Jasper Therapeutics, Inc. and JCR Pharmaceuticals Co., Ltd. are continuously pushing the envelope for clinical innovation, while Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., and Lonza Group AG play critical roles by ensuring the scalability and reliability of stem cell production.

In addition, organizations like Medeze Group, Merck KGaA, and Mesoblast Ltd. are investing in research and development to establish next-generation treatment protocols. Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, and SQZ Biotechnologies Company by Stemcell Technologies are leveraging the latest in cellular engineering to expand therapeutic frontiers. Finally, companies such as Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc., Umoja Biopharma, and Vericel Corporation round out the comprehensive list of key players whose consistent innovation and market presence are setting the pace for the future of stem cell therapy. Each of these companies not only contributes technological expertise and clinical experience but also serves as a benchmark for excellence in advancing regenerative medicine.

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera SAS, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lonza Group AG, Medeze Group, Merck KGaA, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, SQZ Biotechnologies Company by Stemcell Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation. Strategic Recommendations for Maximizing Growth in Stem Cell Therapy

In an evolving industry characterized by rapid advancements and regulatory complexities, industry leaders must adopt strategic measures to sustain growth in the field of stem cell therapy. First, it is essential to continuously invest in research and development to not only improve the therapeutic efficiency of existing modalities but also to discover novel approaches that could address emerging clinical challenges. Maintaining strong collaborations with academic research institutions and global biotechnological networks will enable companies to stay at the forefront of innovation.

Second, companies should prioritize the implementation of rigorous quality control measures and standardized manufacturing processes. This approach will ensure safety, enhance scalability, and promote regulatory compliance throughout the entire production lifecycle. Embracing digital transformations-such as integrating data analytics and artificial intelligence into research pipelines-could provide sharper insights into clinical outcomes and operational efficiencies.

Third, industry stakeholders must tailor their strategies to the unique demands of different regional markets. Customized solutions that account for local regulatory frameworks and market maturity can significantly enhance market penetration and clinical acceptance. It is equally important to build strong, trust-based relationships with healthcare providers by offering continuous education, technical support, and transparent communication regarding the benefits and limitations of various therapies.

Finally, proactive engagement with regulatory bodies is crucial. Keeping abreast of policy changes and participating in shaping future guidelines can preempt regulatory challenges and facilitate smoother market entry. By combining innovation, operational excellence, and strategic regional focus, companies can effectively navigate the competitive landscape and drive sustained growth in the therapeutic domain.

Executive Summary Conclusion: The Future of Stem Cell Therapy

As the stem cell therapy market matures, the convergence of technological breakthroughs, evolving regulatory landscapes, and comprehensive segmentation strategies has painted a promising outlook for the future of regenerative medicine. The journey from laboratory innovation to clinical application is now marked by transformative shifts that are reshaping the standards of care in diverse therapeutic areas. From the rigorous analysis of therapy types and cell sources to the dynamic influence of regional markets and the relentless pursuit of technological excellence by key industry players, every facet of this ecosystem has contributed to building a robust, scalable, and patient-centric therapeutic paradigm.

The continuous evolution of therapeutic strategies coupled with strategic collaborations is further cementing the role of stem cell therapy as an essential component in modern medical practice. As clinical trials yield increasingly positive results and regulatory pathways become more clearly defined, the potential to address complex health issues with precision medicine grows stronger every day. Stakeholders are now presented with a unique opportunity to not only capitalize on these advancements but also to drive the next wave of clinical innovations that could redefine treatment protocols across boundaries.

In summary, the strategic foresight, collaborative efforts, and unwavering commitment to excellence in research and development are setting the stage for breakthroughs that will transform patient care globally. The industry is poised on the brink of a new era, one that promises to deliver enhanced therapeutic outcomes and improved quality of life for patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging global population and awareness about the therapeutic potential of stem cells
      • 5.1.1.2. Government initiatives and favorable regulatory frameworks are promoting stem cell research advancement
      • 5.1.1.3. Growing prevalence of chronic diseases is fueling the need for advanced stem cell therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with stem cell therapy limit accessibility for both patients and providers
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing public and private investment in research and development activities
      • 5.1.3.2. Advancements in cell-based technologies are enhancing the efficacy and applications of stem cell therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the varying regulatory landscape for stem cell therapies
      • 5.1.4.2. Ethical concerns and public perception surrounding the use of stem cells
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Growing applications of autologous therapy owing to minimizing the risk of immune rejection and transmission of infectious diseases
    • 5.2.2. Cell Source: Proliferating significance of neural stem cells due to the ability to differentiate into various cell types within the central nervous system
    • 5.2.3. End User: Increasing adoption of stem cell therapy in biotechnology & pharmaceutical companies for addressing neurodegenerative diseases and cardiovascular disorders
    • 5.2.4. Application: Rising applications in drug discovery and development owing to their ability to model diseases
    • 5.2.5. Therapeutic Areas: Significant benefits of stem cell therapy in cardiovascular diseases owing to cardiac repair and regeneration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Allogeneic Therapy
  • 6.3. Autologous Therapy

7. Stem Cell Therapy Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adult Stem Cells
    • 7.2.1. Hematopoietic Stem Cells
    • 7.2.2. Mesenchymal Stem Cells
    • 7.2.3. Neural Stem Cells
  • 7.3. Embryonic Stem Cells
  • 7.4. Induced Pluripotent Stem Cells
  • 7.5. Perinatal Stem Cells
    • 7.5.1. Amniotic Fluid Stem Cells
    • 7.5.2. Placental Stem Cells
    • 7.5.3. Umbilical Cord Stem Cells

8. Stem Cell Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutions
  • 8.3. Biotechnology & Pharmaceutical Companies
  • 8.4. Hospitals & Specialty Clinics

9. Stem Cell Therapy Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Discovery and Development
  • 9.3. Regenerative Medicine
  • 9.4. Tissue Engineering

10. Stem Cell Therapy Market, by Therapeutic Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Hematology
  • 10.4. Musculoskeletal Disorders
  • 10.5. Neurological Disorders
  • 10.6. Oncology

11. Americas Stem Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Stem Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Stem Cell Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. REGiMMUNE and Kiji Therapeutics unite to advance Treg-focused stem cell therapies
    • 14.3.2. Evotec and Novo Nordisk partnership advances stem cell therapy innovations for scalable solutions
    • 14.3.3. Collaboration between Somite Therapeutics and OmniaBio Inc. aims to revolutionize stem cell therapy with AI-driven approaches for Duchenne muscular dystrophy
    • 14.3.4. Bioserve India's launch of advanced stem cell products propels innovative research and therapies in India's regenerative medicine landscape
    • 14.3.5. Cell BioEngines secures USD 2 million funding to advance 'off-the-shelf' hematopoietic stem cell therapies and initiate multicenter clinical trials
    • 14.3.6. OrganaBio revolutionizes advanced therapy development with on-demand GMP-compliant hematopoietic stem cells
    • 14.3.7. FDA expands approval for CARVYKTI as the first BCMA-targeted therapy advancing multiple myeloma treatment
    • 14.3.8. Strategic partnership accelerates stem cell therapy development through streamlined collaboration
    • 14.3.9. Fujifilm to Invest USD 200 Million in Cell Therapy Production
    • 14.3.10. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
    • 14.3.11. Merger between Selecta Biosciences and Cartesian Therapeutics pioneers RNA cell therapy advancements
    • 14.3.12. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
    • 14.3.13. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
    • 14.3.14. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
    • 14.3.15. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
    • 14.3.16. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
    • 14.3.17. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
    • 14.3.18. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
    • 14.3.19. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
    • 14.3.20. Novo Nordisk to Expand R&D Presence in Greater Boston Area
    • 14.3.21. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.22. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
    • 14.3.23. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 14.4.2. JCR Pharmaceuticals Co., Ltd.
    • 14.4.3. Novo Nordisk A/S
    • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. Anterogen Co., Ltd.
  • 2. Astellas Pharma Inc.
  • 3. Beike Biotechnology Co., Ltd.
  • 4. BrainStorm Cell Therapeutics Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. CellProthera SAS
  • 7. Fate Therapeutics, Inc.
  • 8. Gamida Cell Ltd.
  • 9. Garuda Therapeutics
  • 10. Holostem Terapie Avanzate S.r.l.
  • 11. Jasper Therapeutics, Inc.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Juvena Therapeutics Inc.
  • 14. Kangstem Biotech Co., Ltd.
  • 15. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 16. Lonza Group AG
  • 17. Medeze Group
  • 18. Merck KGaA
  • 19. Mesoblast Ltd.
  • 20. Novo Nordisk A/S
  • 21. Plasticell
  • 22. ReNeuron Group PLC
  • 23. SQZ Biotechnologies Company by Stemcell Technologies
  • 24. Takara Bio Inc.
  • 25. Thermo Fisher Scientific Inc.
  • 26. U.S. Stem Cell Inc
  • 27. Umoja Biopharma
  • 28. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. STEM CELL THERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 328. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023